Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 201 clinical trials
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.

Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac …

chemotherapy regimen
chemoradiotherapy
treatment regimen
cancer chemotherapy
teratogenicity
  • 0 views
  • 19 Feb, 2024
Understanding Factors That Influence Electronic Cigarette Nicotine Delivery Through PET Imaging of Beta-2 Nicotinic Acetylcholine Receptors

The goal of this proposal is to test the overall hypothesis that e-cigarettes (ECs) provide efficient nicotine delivery to the brain and arterial blood in non-EC-nave smokers and e-cigarette users and that EC liquid characteristics modulate this effect. This study will test the hypothesis through complementary methods that include [ …

  • 0 views
  • 19 Feb, 2024
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective:

<ul>
  • To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B
  • ul>

    Secondary Objective:

    <ul>
  • To characterize the safety and tolerability
  • To characterize the pharmacokinetics (PK)
  • ul>

    hemophilia
    fitusiran
    haemophilia a
    antihemophilic factor
    factor ix
    • 0 views
    • 19 Feb, 2024
    • 11 locations
    Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

    Primary Objective:

    <ul>
  • To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B
  • ul>

    Secondary Objective:

    <ul>
  • To characterize the safety and tolerability
  • To characterize the pharmacokinetics (PK)
  • ul>

    hemophilia
    fitusiran
    haemophilia a
    antihemophilic factor
    factor ix
    • 0 views
    • 19 Feb, 2024
    • 6 locations
    Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

    Primary Objectives:

    <ul>
  • To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV)
  • To evaluate the pharmacokinetics (PK) of SC and IV isatuximab
  • ul>

    Secondary Objectives:

    <ul>
  • To estimate absolute bioavailability of SC and IV isatuximab
  • To measure receptor occupancy (RO) after isatuximab SC versus IV …

    proteasome inhibitor
    hydrochloride salt
    hepatitis
    arginine
    hbv dna
    • 0 views
    • 19 Feb, 2024
    • 13 locations
    • 0 views
    • 19 Feb, 2024
    • 23 locations
    • 0 views
    • 29 Nov, 2024
    • 20 locations
    • 0 views
    • 19 Feb, 2024
    • 7 locations
    Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

    Primary Objectives:

    <ul>
  • Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)
  • Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when …

    multiple myeloma
    bone marrow plasma cells
    bone marrow procedure
    dexamethasone
    smoldering myeloma
    • 0 views
    • 19 Feb, 2024
    • 16 locations
    Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

    Primary Objectives:

    <ul>
  • Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)
  • Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared …

    multiple myeloma
    bone marrow plasma cells
    bone marrow procedure
    dexamethasone
    smoldering myeloma
    • 0 views
    • 19 Feb, 2024
    • 11 locations